Clinical trials: No Disease
Colorectal Neoplasms, Adenocarcinoma of the Colon
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX…
- Conditions
- Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT02425683
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Chagas Disease
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
This is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic Chagas disease. The primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response…
- Trial name
- STOP CHAGAS (NCT01377480)
- Testing
- Posaconazole, Benznidazole
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome
A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)
The purpose of this study is determine if SCH 530348 2.5 mg tablets containing a high percentage of drug as the free base are equivalent to tablets with the standard percentage when given to participants.
- Trial name
- NCT01358344
- Testing
- Pantoprazole, SCH 530348 (high percentage), SCH 530348 (standard percentage)
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Retinitis Pigmentosa, Retinitis
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- RESTORE (NCT04945772)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Nanoscope Therapeutics Inc.
Asthma
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
A study to compare the bronchodilatory effect of a single dose of Mometasone Furoate/Formoterol Fumarate (MF/F) pressurized metered dose inhaler (MDI) delivered with and without an AeroChamber Plus® with Flow-Vu® Anti-Static…
- Trial name
- NCT01258803
- Testing
- Formoterol Fumarate DPI, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
- Volunteers
- 92 people
- Sponsor
- Organon and Co
Multiple Sclerosis
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
This study is designed to compare injection site reactions with or without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection.
- Trial name
- NCT00220922
- Testing
- Alcohol Wipes vs. No Alcohol Wipes
- Volunteers
- 50 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Myeloma
Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy.
- Trial name
- NCT00732641
- Testing
- Peginterferon
- Volunteers
- 244 people
- Sponsor
- Merck Sharp & Dohme LLC
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Arthritis, Rheumatoid
A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)
This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist.
- Trial name
- NCT01313520
- Testing
- Infliximab
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both.
- Trial name
- NCT00002334
- Testing
- Saquinavir, Zidovudine, Zalcitabine
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 3,000 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Neoplasms
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
- Trial name
- NCT00768664
- Testing
- PF-00299804
- Where
- 10 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuromuscular Blockade, Arthroplasty, Replacement, Hip
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on…
- Conditions
- Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Blood Coagulation
- Trial name
- NCT01422304
- Testing
- Sugammadex, neostigmine and glycopyrrolate or atropine
- Volunteers
- 1,198 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.
- Trial name
- NCT00300508
- Testing
- Anastrozole
- Where
- 51 sites in Austria
- Volunteers
- 856 people
- Sponsor
- AstraZeneca
Advanced Breast Cancer
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.
- Trial name
- MONALEESA-3 (NCT02422615)
- Testing
- Ribociclib, Fulvestrant
- Where
- 174 sites in United States, Australia and 28 more
- Volunteers
- 726 people
- Sponsor
- Novartis Pharmaceuticals
Seborrheic Dermatitis
Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face
Clinical single-blind randomized comparison with the overall objective of evaluating the clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of seborrheic dermatitis on the face.
- Trial name
- 13244/2009 (NCT01024374)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Allergisa Pesquisa Dermato-Cosmetica LTDA
Rhinoconjunctivitis, Rhinitis
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced…
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00978029
- Testing
- SCH 39641
- Volunteers
- 203 people
- Sponsor
- ALK-Abelló A/S
Breast Cancer
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
- Trial name
- Ax-003 (NCT00638391)
- Testing
- Anastrozole
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Gastro-oesophageal Reflux
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
The purpose of this observational study (this means that no drug is being tested in this study) is to obtain updated and detailed information about the Gastroesophageal Reflux Disease (GERD) specificities in European patients.
- Conditions
- Gastroesophageal Reflux Disease, Gastro-oesophageal Reflux, Gastro-Esophageal Reflux, Esophageal Reflux
- Trial name
- PROFILE (NCT01601379)
- Volunteers
- 7,964 people
- Sponsor
- Janssen-Cilag International NV
Heart Failure, Cardiac Resynchronization Therapy
Safety and Performance Aspects of CRT-DX System in Patients With Sinus Rhythm
The conventional CRT-D system consists of 3 leads in patients with Heart Failure (HF). A part of HF patients have non-impaired sinus node function and will not be stimulated in the right atrium.
- Trial name
- BIO|REDUCE (NCT03839121)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 21 sites in Austria, Czechia and 2 more
- Volunteers
- 113 people
- Sponsor
- Biotronik SE & Co. KG